At the event, GenScript unveiled the integration and upgrading of the original CDMO platform and the release of its latest brand, GenScript ProBio. The new brand is dedicated to providing end-to-end service from discovery to commercialization.
For the past 16 years, since 2004, GenScript has gradually expanded its reach in the antibody drug discovery segment and established its capabilities in process development, helping many customers with their IND approvals during the period.
In 2019, GenScript opened the Biologics Development Business Unit (BDBU), the predecessor of GenScript ProBio, and appointed Brian Min, senior vice president at Samsung Bioepis, to join as chief executive officer and form a management team. The core members of the team each have more than 15 years working experience at recognized international firms across the sector, including Roche, Pfizer, Henlius and Innovent, among others.
"The GenScript CDMO platform has established strong antibody capabilities within just 18 months since launch and has accumulated considerable experience in cell and gene therapy," said Dr. Min at the launch of the brand. "GenScript ProBio's one-stop antibody drug development solutions will proactively provide clients with end to end service from target to commercialization. Looking beyond China and the Asia Pacific region, many large multinational companies in the U.S. and Europe have also established productive partnerships with us. Operating under the principle of 'Innovation through Collaboration', we fully expect to drive the development and progress of the whole industry together with our customers."